William Blair analyst Raju Prasad maintained a Buy rating on Cellectis SA (CLLS) today. The company’s shares closed yesterday at $18.71.
According to TipRanks.com, Prasad is a 5-star analyst with an average return of 25.6% and a 66.7% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Global Blood Therapeutics, and Logicbio Therapeutics Inc.
Currently, the analyst consensus on Cellectis SA is a Strong Buy with an average price target of $36, which is a 92.4% upside from current levels. In a report issued on March 20, Oppenheimer also assigned a Buy rating to the stock.
See today’s analyst top recommended stocks >>
Based on Cellectis SA’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $22.98 million. In comparison, last year the company had a GAAP net loss of $25.49 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants.
